Postpartum Hemorrhage Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Postpartum hemorrhage devices market size in 2026 is estimated at USD 1.08 billion, growing from 2025 value of USD 1.03 billion with 2031 projections showing USD 1.38 billion, growing at 5.05% CAGR over 2026-2031. This report is Segmented by Product Type (Uterine Tamponade Devices, Non-Pneumatic Anti-Shock Garments (NASG), Prefilled Uterotonic Injection Systems, and More), End User (Hospitals, Maternity Clinics & Birthing Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Postpartum Hemorrhage Devices Market Trends and Insights

Vacuum-Induced Hemorrhage-Control Devices Gain FDA & EU Approvals

Regulators in both the United States and the European Union have shortened review cycles for vacuum-induced systems, turning a formerly experimental concept into a mainstream alternative that complements or replaces balloon tamponade. The FDA’s 510(k) pathway now admits designs that incorporate closed-loop pressure sensors and automatic safety valves, reassuring clinicians about tissue-trauma risks and pushing adoption across large obstetric units. Parallel alignment under the EU Medical Device Regulation has reduced average CE-marking time from 18-24 months to 8-12 months, amplifying first-mover advantages for firms able to furnish randomized-trial evidence. Hospital technology-assessment committees weigh these data alongside cost-of-care metrics, often finding shorter procedure times and lower transfusion rates relative to balloon techniques. The resulting procurement decisions cascade through group-purchasing organizations, expanding addressable volumes and strengthening the overall postpartum hemorrhage devices market.

Reimbursement Expansion for Bakri/EBB Balloons in EU & U.S.

Coverage decisions issued in 2024 eliminated a long-standing financial hurdle for intrauterine balloons. Medicare now reimburses prophylactic as well as emergency use, turning the device from a cost center into a revenue-compatible intervention for hospitals. Major European payers, led by Germany’s statutory insurers and the U.K.’s NHS, have mirrored this stance with procedure fees ranging EUR 200-450 (USD 210-475) per case. Commercial insurers in the United States now cover 78 % of eligible deliveries, creating predictable revenue streams that justify staff-training budgets and inventory build-ups. Device makers exploit this policy tailwind with outcome-based contracting, placing capital equipment at no upfront cost in exchange for per-procedure payments. Such models further cement the postpartum hemorrhage devices market in hospital formularies.

Device Sticker-Price Greater Than USD 900 Limits Uptake in Tier-2 Hospitals

Mid-tier facilities typically allocate device budgets 18-24 months in advance and require demonstrated utilization of at least 15 cases per month to meet return-on-investment thresholds. Premium systems priced beyond USD 900 frequently miss this benchmark, confining their penetration to high-volume urban centers. Leasing and rental programs attempt to distribute costs but often raise total ownership expenses because of bundled maintenance fees. The resulting two-tiered technology landscape leaves rural communities dependent on lower-cost balloon kits that may lack advanced safety features such as pressure sensors. This dynamic slows diffusion and dampens the postpartum hemorrhage devices market trajectory in sizeable yet budget-constrained segments.

Other drivers and restraints analyzed in the detailed report include:

• WHO-Backed Roll-Out of Low-Cost Condom-UBT Kits in LMICs
• Integration of AI-Based PPH Risk-Scoring into EHR Platforms
• Shortage of PPH-Trained Obstetricians in Rural Regions

Segment Analysis

Uterine tamponade devices anchored 39.92 % of the postpartum hemorrhage devices market in 2025 on the strength of entrenched clinical protocols and favorable reimbursement. Balloon systems, including Bakri and EBB variants, dominate due to broad obstetric training and decades of outcome data. Vacuum-induced versions are expanding share after recent 510(k) clearances demonstrated shorter intervention times and reduced transfusion requirements. Non-pneumatic anti-shock garments supply a rapid-stabilization option in pre-hospital settings, whereas heat-stable oxytocin injectors plug pharmacologic gaps where cold-chain reliability is low. The postpartum hemorrhage devices market size attached to balloon products is projected to expand at a 4.05% CAGR through 2031 as tender volumes grow in government facilities.

AI-enabled detection platforms record a 11.72% CAGR, the highest among all product lines, because predictive analytics align with payer incentives that reward avoided complications. Vendors bundle algorithmic risk scores with cloud-based dashboards, subscription support and periodic model retraining. Hospitals that integrate these modules into obstetric EHR workflows report procedure-related cost reductions that offset licensing fees. Topical hemostatic sealants occupy a surgical adjunct niche, often packaged alongside cesarean-section kits. Future product roadmaps point toward unified platforms that combine monitoring, mechanical intervention and drug delivery, indicating that the postpartum hemorrhage devices market will increasingly favor integrated ecosystems over single-purpose devices.

Complete Report Scope:

• By Product Type
  • Uterine Tamponade Devices
    • Balloon Tamponade
    • Vacuum-Induced Devices
  • Non-Pneumatic Anti-Shock Garments (NASG)
  • Prefilled Uterotonic Injection Systems
  • Topical Hemostatic & Sealant Applicators
  • AI-enabled Early Detection & Monitoring Tools
• By End User
  • Hospitals
  • Maternity Clinics & Birthing Centers
  • Ambulatory Surgical Centers
  • Homebirth & Community Healthcare Providers
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 35.02 % of revenue in 2025, supported by dense insurance coverage, rapid regulatory clearance and robust clinical-trial infrastructure. Medicare’s broad reimbursement of prophylactic balloon use removes financial friction, while private payers follow established coverage determinations. Large group-purchasing organizations negotiate volume discounts, boosting unit throughput. Academic consortia continuously publish peer-reviewed outcome studies, reinforcing evidence-based procurement. Provincial formularies in Canada echo U.S. trends, creating continent-wide homogeneity that accelerates technology diffusion and solidifies the postpartum hemorrhage devices market.

Asia-Pacific is the fastest-growing territory at 8.28% CAGR. China’s Healthy China 2030 agenda earmarks substantial provincial outlays for maternal-mortality reduction, driving high-volume procurement of balloon and NASG systems. India’s National Health Mission allocated INR 192 billion (USD 2.3 billion) toward obstetric-care upgrades in 2024, part of which finances AI-infused monitoring pilots across district hospitals. ASEAN regulatory harmonization enables simultaneous device launches in Malaysia, Indonesia and Thailand, providing economies of scale that accelerate price erosion and broaden access. As disposable incomes rise and urban birth volumes increase, the postpartum hemorrhage devices market embeds deeper into private obstetric chains that cater to middle-class families.

Europe records steady mid-single-digit expansion under the EU Medical Device Regulation’s tightened but harmonized compliance regime. Nordic nations lead per-capita adoption of AI-risk-scoring tools given their high EHR digitization rates. Central-and-Eastern Europe relies heavily on EU cohesion funds to refresh equipment lines, creating clustered tender opportunities for mid-tier manufacturers. The Middle East and Africa offer long-run upside sparked by sovereign investment in maternity-hospital buildouts and WHO-sponsored training programs. South America’s Mercosur tariff reductions ease cross-border device shipment, and expanding private insurance coverage in Brazil and Mexico underwrites elective prophylactic use. Collectively, these trends extend the geographic footprint of the postpartum hemorrhage devices market.

List of Companies Covered in this Report:

• Cook Group
• Utah Medical Products
• Organon & Co. (Alydia Health)
• Laborie
• Beckton Dickinson
• Teleflex
• Sinapi Biomedical
• 3rd Stone Design, Inc.
• Boen Healthcare Co., Ltd.
• Pregna International Ltd.
• Go Medical Industries Pty Ltd.
• Celox PPH
• The Cooper Companies
• Matria Health Technologies (HemoSquid)
• Zoex NIASG
• Maternova Inc.
• Blue Fuzion Group
• MedGyn Products
• Ferring Pharmaceuticals
• PATH (Every Second Matters-UBT)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support